Literature DB >> 1318228

A novel ETA antagonist (BQ-123) inhibits endothelin-1-induced phosphoinositide breakdown and DNA synthesis in rat vascular smooth muscle cells.

S Eguchi1, Y Hirata, M Ihara, M Yano, F Marumo.   

Abstract

The effects of a novel cyclic pentapeptide (BQ-123), an endothelin (ET) antagonist selective for the ETA receptor subtype, on phosphoinositide breakdown and DNA synthesis stimulated by ET-1 were studied in cultured rat vascular smooth muscle cells (VSMC). BQ-123 competitively inhibited the binding of [125I]ET-1 to VSMC with the apparent Ki of 4 x 10(-9) M. BQ-123 dose-dependently inhibited formation of inositol-1,4,5-trisphosphate and [3H]thymidine uptake stimulated by ET-1. These data suggest that the ET-1-induced DNA synthesis in VSMC is mainly mediated by ETA receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318228     DOI: 10.1016/0014-5793(92)80451-l

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Endothelins mediate neutrophil activation, ProMMP-9 release and endothelial cell detachment.

Authors:  Monica C Toffoli; Bichoy H Gabra; Catarina F P Teixeira; Pierre Sirois; Sonia Jancar
Journal:  Inflammation       Date:  2007-01-13       Impact factor: 4.092

2.  Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells.

Authors:  Kerstin Ebefors; Robert J Wiener; Liping Yu; Evren U Azeloglu; Zhengzi Yi; Fu Jia; Weijia Zhang; Margaret H Baron; John C He; Börje Haraldsson; Ilse Daehn
Journal:  Kidney Int       Date:  2019-05-22       Impact factor: 10.612

3.  Glomerular Endothelial Mitochondrial Dysfunction Is Essential and Characteristic of Diabetic Kidney Disease Susceptibility.

Authors:  Haiying Qi; Gabriella Casalena; Shaolin Shi; Liping Yu; Kerstin Ebefors; Yezhou Sun; Weijia Zhang; Vivette D'Agati; Detlef Schlondorff; Börje Haraldsson; Erwin Böttinger; Ilse Daehn
Journal:  Diabetes       Date:  2016-11-29       Impact factor: 9.461

Review 4.  Endothelin: potential role in development and disease.

Authors:  V Kon; A Fogo
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

5.  Selective activation of excitation-contraction coupling pathways by ET(A) and ET(B) receptors in guinea-pig tracheal smooth muscle.

Authors:  T Inui; H Ninomiya; Y Sasaki; M Makatani; Y Urade; T Masaki; T Yamamura
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  Regional modulation of cyclic nucleotides by endothelin-1 in rat pulmonary arteries: direct activation of G(i)2-protein in the main pulmonary artery.

Authors:  I Mullaney; D M Vaughan; M R MacLean
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

7.  A selective endothelin ETA antagonist, BQ-123, inhibits 125I-endothelin-1 (125I-ET-1) binding to human meningiomas and antagonizes ET-1-induced proliferation of meningioma cells.

Authors:  N Kitagawa; K Tsutsumi; M Niwa; S Yamaga; T Anda; H Khalid; A Himeno; K Taniyama; S Shibata
Journal:  Cell Mol Neurobiol       Date:  1994-04       Impact factor: 5.046

8.  Endothelin-3 induces hypertrophy of cardiomyocytes by the endogenous endothelin-1-mediated mechanism.

Authors:  M Tamamori; H Ito; S Adachi; H Akimoto; F Marumo; M Hiroe
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

9.  Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis.

Authors:  Ilse Daehn; Gabriella Casalena; Taoran Zhang; Shaolin Shi; Franz Fenninger; Nicholas Barasch; Liping Yu; Vivette D'Agati; Detlef Schlondorff; Wilhelm Kriz; Borje Haraldsson; Erwin P Bottinger
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 10.  Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease.

Authors:  G Noll; R R Wenzel; T F Lüscher
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.